1,1-dimethylethyl 4-(methylsulfonyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate | 871500-92-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 1,1-dimethylethyl 4-(methylsulfonyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate
• 英文别名: t-butyl 4-(methylsulfonyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate；tert-butyl 4-methylsulfonyl-2,3,6,7,9,10-hexahydro-[1,4]oxazino[2,3-h][3]benzazepine-8-carboxylate
• CAS: 871500-92-4
• 化学式: C₁₈H₂₆N₂O₅S
• 分子量: 382.481
• InChiKey: RQQHHEXGANEMOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  84.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  t-butyl 3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate 、 甲基磺酰氯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 25.0h， 生成 1,1-dimethylethyl 4-(methylsulfonyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate
  参考文献：
  名称：

  Benzazepine Compound

  摘要：

  提供的是一种化合物，可用作治疗或预防与5-HT 2C 受体相关的疾病的药剂，特别是尿失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖等。 【解决方案】本发明者研究了具有5-HT 2C 受体激动剂活性的化合物，这种活性有望作为治疗或预防尿失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖等的药物组合物的有效成分。他们发现本发明的苯并环己酮类化合物具有出色的5-HT 2C 受体激动剂活性，从而完成了本发明。换句话说，本发明的苯并环己酮类化合物具有5-HT 2C 受体激动剂活性，可用作治疗或预防与5-HT 2C 受体相关的疾病的药剂，特别是尿失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖等。

  公开号：

  US20110269744A1

文献信息

• COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF"
  申请人：Bonanomi Giorgio

  公开号：US20100016287A1

  公开（公告）日：2010-01-21

  Compounds of formula (I) wherein A is a 5 or 6 membered heteroaromatic ring or a 5 or 6 membered heterocyclic ring, and which are useful for treating mental disorders such as schizophrenia are set out herein.

  本文介绍了式子（I）中A为5或6成员杂芳环或5或6成员杂环的化合物，可用于治疗精神障碍，如精神分裂症。
• Compounds having affinity for dopamine D3 receptor and uses thereof
  申请人：Glaxo Group Limited

  公开号：US07989444B2

  公开（公告）日：2011-08-02

  Compounds of formula (I) wherein A is a 5 or 6 membered heteroaromatic ring or a 5 or 6 membered heterocyclic ring, and which are useful for treating mental disorders such as schizophrenia are set out herein.

  本文介绍了化学式(I)中A为5或6元杂芳环或5或6元杂环的化合物，这些化合物可用于治疗精神障碍，如精神分裂症。
• BENZAZEPINE COMPOUND
  申请人：Koshio Hiroyuki

  公开号：US20130012496A1

  公开（公告）日：2013-01-10

  Provided is a compound which is useful as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT 2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT 2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT 2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT 2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

  提供了一种化合物，可用作治疗或预防5-HT2C受体相关疾病的药剂，特别是尿失禁，如压力性尿失禁，切勿性尿失禁，混合性尿失禁等，性功能障碍，如勃起功能障碍综合症等，肥胖症等。本发明人研究了具有5-HT2C受体激动剂活性的化合物，并发现本发明的苯并氮杂环化合物具有优异的5-HT2C受体激动剂活性，从而完成了本发明。也就是说，本发明的苯并氮杂环化合物具有5-HT2C受体激动剂活性，并可用作治疗或预防5-HT2C受体相关疾病的药剂，特别是尿失禁，如压力性尿失禁，切勿性尿失禁，混合性尿失禁等，性功能障碍，如勃起功能障碍综合症等，肥胖症等。
• Benzazepine compound
  申请人：Koshio Hiroyuki

  公开号：US09108977B2

  公开（公告）日：2015-08-18

  Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

  提供了一种化合物，可作为治疗或预防5-HT2C受体相关疾病的药物，特别是治疗失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖症等。本发明人研究了具有5-HT2C受体激动剂活性的化合物，并发现本发明的苯并氮杂环化合物具有优异的5-HT2C受体激动剂活性，从而完成了本发明。也就是说，本发明的苯并氮杂环化合物具有5-HT2C受体激动剂活性，可作为治疗或预防5-HT2C受体相关疾病的药物，特别是治疗失禁，如压力性尿失禁、急迫性尿失禁、混合性尿失禁等，性功能障碍，如勃起功能障碍综合征等，肥胖症等。
• [EN] COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF<br/>[FR] COMPOSES PRESENTANT UNE AFFINITE POUR LE RECEPTEUR DE LA DOPAMINE D3 ET LEURS UTILISATIONS
  申请人：GLAXO GROUP LTD

  公开号：WO2005118549A3

  公开（公告）日：2006-04-13